KMB Kimberly-Clark
Kenvue merger raises margin potential; the model's pre-deal financials vs post-deal shares understate fair value.
The story
Kimberly-Clark is now a combined tissue/personal-care and Kenvue consumer-health franchise. The share count (614M) shows the Kenvue deal has closed, but the revenue and net-debt figures here are still standalone, pre-merger numbers. The core business is mature: brands like Huggies and Kleenex face private-label pressure, while Kenvue adds higher-margin, faster-growing brands like Tylenol, Neutrogena and Listerine. The rest of the story is integration: about $1.9B of targeted cost synergies against higher leverage and Tylenol litigation risk.
Organic growth goes from 2.0% to 2.5% because Kenvue's categories grow a little faster. Target margin goes from 16% to 18%, reached over 5 years, as Kenvue's roughly 20% margin and partial synergy capture outweigh integration costs. Beta goes from 0.70 to 0.75 for the higher post-deal leverage. Important caveat: the model's base revenue (16.57B) and net debt (6.48B) leave out Kenvue's roughly 15B of revenue and the acquired debt, but the share count already includes the shares issued in the deal. The computed value will therefore understate fair value by roughly half and should not be read as a sell signal until the financials are re-based to the combined company.
Value drivers
| Revenue growth (Y1) | 2.5% |
| Terminal growth | 2.5% |
| Forecast horizon | 7y |
| Target operating margin | 18.0% |
| Years to target margin | 5 |
| Sales-to-capital | 2.00 |
| Beta | 0.75 |
| Failure probability | 2.0% |
| Cost of capital (WACC) | 8.0% |
| Terminal WACC | 9.1% |
Valuation bridge
| PV of explicit FCFF | 10.12B |
| PV of terminal value | 19.05B |
| Equity value | 22.09B |
| ÷ shares → per share | $36.00 |
Projected free cash flow to the firm
| Yr | Revenue | Growth | Margin | NOPAT | Reinvest | FCFF | PV |
|---|---|---|---|---|---|---|---|
| 1 | 16.98B | 2.5% | 15.1% | 1.82B | 207.07M | 1.61B | 1.49B |
| 2 | 17.40B | 2.5% | 15.8% | 1.95B | 212.25M | 1.74B | 1.49B |
| 3 | 17.84B | 2.5% | 16.6% | 2.09B | 217.56M | 1.87B | 1.49B |
| 4 | 18.29B | 2.5% | 17.3% | 2.24B | 223.00M | 2.01B | 1.48B |
| 5 | 18.74B | 2.5% | 18.0% | 2.39B | 228.57M | 2.16B | 1.47B |
| 6 | 19.21B | 2.5% | 18.0% | 2.45B | 234.29M | 2.21B | 1.39B |
| 7 | 19.69B | 2.5% | 18.0% | 2.51B | 240.14M | 2.27B | 1.32B |
Key risks
- Integration execution and synergy shortfall at roughly $1.9B targeted
- Tylenol/acetaminophen litigation and reputational overhang inherited from Kenvue
- Private-label share gains and pulp/input cost inflation squeezing tissue and diaper margins
Catalysts
- First full quarters of combined reporting with synergy run-rate disclosure
- Deleveraging toward about 3x net debt/EBITDA, freeing capacity for dividend growth